The CB1 cannabinoid receptor is a constitutively active receptor that can sequester G i/o -proteins and prevent other G i/ocoupled receptors from signaling (Bouaboula et al., 1997; Pan et al., 1998; Vasquez and Lewis, 1999) . G-protein sequestration occurs because the population of CB1 cannabinoid receptors exists in both an inactive G-protein-precoupled RG GDP state and a constitutively active R*G GTP state. We tested the hypothesis that the distal C-terminal tail acts to prevent G-protein activation. We found that truncation of the distal C-terminal tail of the CB1 receptor (CB1-417) enhanced both the constitutive activity and the ability of the receptor to sequester G-proteins. In addition, we tested the hypothesis that the conserved aspartate (D2.50) in the second transmembrane domain of the CB1 cannabinoid receptor is crucial for constitutive activity and G-protein sequestration. We found that the mutation of aspartate to asparagine (CB1-D164N) abolished G-protein sequestration and constitutive receptor activity without disrupting agonist-stimulated activity. We conclude that the CB1-D164N mutation and the C-terminal truncation shift the population of receptors in opposite directions. The CB1-D164N mutation shifts the receptor into an inactive R state upcoupled from G-proteins, whereas the C-terminal truncation (CB1-417) shifts the receptor into the active R*G GTP state. Thus the distal C-terminal tail acts to constrain the receptor from activating G-proteins, whereas the aspartate (D2.50) in the second transmembrane domain stabilizes the receptor in both the inactive RG GDP state and the active R*G GTP state.
The discovery of the CB1 cannabinoid receptor (Howlett and Fleming, 1984; Howlett, 1985; Matsuda et al., 1990 ) and the demonstration that cannabinoid receptors are the most abundant G-protein-coupled receptor in the brain (Herkenham et al., 1990 ) stimulated questions about its physiological function. The active ingredient in marijuana, ⌬ 9 -tetrahydrocannabinol, binds to the CB1 receptor and is effective in alleviating pain and nausea, stimulating appetite, and affecting memory and mood. Endogenous cannabinoid ligands, anandamide and 2-arachidonylglycerol, are made in response to neuronal activity (Devane et al., 1992; Di Marzo et al., 1994 Stella et al., 1997) and act as fast retrograde messengers (Kreitzer and Regehr, 2001; OhnoShosaku et al., 2001; Wilson and Nicoll, 2001) . CB1 receptors are found in high density in GABAergic neurons (Matsuda et al., 1993; Tsou et al., 1998) , and CB1 receptors inhibit GABA release (Katona et al., 1999; Hajos et al., 2000; Hoffman and Lupica, 2001; Wilson and Nicoll, 2001 ) by inhibiting Ca 2ϩ channels (Mackie and Hille, 1992; Mackie et al., 1995; Pan et al., 1996; Twitchell et al., 1997; Shen and Thayer, 1998; Sullivan, 1999) .
The CB1 cannabinoid receptor is unusual because it is constitutively active and therefore is able to transduce a biological signal in the absence of ligand (Bouaboula et al., 1997; Landsman et al., 1997; MacLennan et al., 1998; Pan et al., 1998; Coutts et al., 2000) . The CB1 receptor is also unusual in that it can sequester G i /o -proteins and prevent other G i /o -coupled receptors from signaling (Bouaboula et al., 1997; Vasquez and Lewis, 1999) . However, the structural basis of constitutive activity and G-protein sequestration is unknown. A peptide fragment representing the juxtamembrane C-terminal tail of the CB1 cannabinoid receptor can activate G-proteins (Howlett et al., 1998) . We hypothesized that the proximal C-terminal tail of the CB1 cannabinoid receptor is responsible for constitutive activity and that the distal C-terminal tail acts to prevent G-protein activation. We predicted that removal of the distal C-terminal tail (CB1-417) would enhance both the constitutive activity and the ability of the CB1 cannabinoid receptor to sequester G-proteins.
Mutation of aspartate to asparagine in the second transmembrane domain of the CB1 receptor (CB1-D164N) selectively blocked coupling to inwardly rectifying K ϩ channels while leaving coupling to the Ca 2ϩ channels intact . Thus the CB1-D164N mutation may destabilize G-protein coupling. We therefore hypothesized that the aspartate in the second transmembrane domain of the CB1 receptor plays a crucial role in stabilizing the G-protein-coupled conformation of the receptor. We predicted that the CB1-D164N mutation would destabilize G-protein coupling and block the ability of the CB1 receptor to sequester G-proteins and to adopt a constitutively active conformation. We found that the CB1-D164N mutant receptor was not constitutively active and could not sequester G-proteins. We also found that truncation of the distal C terminal resulted in a receptor with enhanced constitutive activity and a greater ability to sequester G-proteins.
MATERIALS AND METHODS
Molecular biolog ical procedures. The human brain cannabinoid receptor CB1 cDNA (from Dr. Tom I. Bonner, Laboratory of C ell biology, National Institute of Mental Health, Bethesda, MD) was subcloned into the mammalian expression vector pCI (Promega, Madison, W I) as de-scribed previously (Pan et al., 1996) . The C -terminal-truncated CB1-417 receptor was constructed by using PCR techniques to delete amino acids 418 -472. To truncate the CB1 receptor, we amplified a DNA segment from a restriction site (StuI) in the middle of the coding sequence of CB1 to the truncation site by PCR via Taq polymerase (Promega). The upstream PCR primer included the StuI site, GTG CGT CAT CC T CCA C TC. A stop codon was included in the downstream primer, CGA GAT C TC GTC AGC C TT CAC AAG AGG GAA AC. The PCR conditions were 30 cycles of 95°C for 1 min, 50°C for 1 min, and 72°C for 1.5 min. The PCR product was subcloned into pGEM-T (Promega). Both pCI-CB1 and the PCR product in pGEM-T were digested with StuI and NotI. The PCR fragment excised from pGEM-T was ligated back into pCI-CB1 to replace the original excised segment and was transformed into JM109 cells (Promega). Colonies were screened for ligation of the PCR fragment by size restriction analysis by using StuI and NotI and were confirmed by sequencing (sequencing facility of the Medical College of Georgia). The mutant CB1 receptor in which the aspartate in the second transmembrane domain was mutated to asparagine, CB1-D164N in pcDNA3, was a gift from Dr. Kenneth Mackie (University of Washington, Seattle, WA). Preparation of plasmid DNA was accomplished with a plasmid prep kit (Qiagen, Santa C larita, CA).
Neuron preparation and microinjection. Superior cervical ganglion (SCG) neurons were isolated from adult male Wistar rats (350 -375 gm) in accordance with National Institutes of Health Guidelines for the Care and Use of Laborator y Animals in Research and approved by the Committee on Animal Use for Research and Education at the Medical College of Georgia. All efforts were made to minimize animal suffering and to use only the number of animals necessary to produce reliable scientific data. Isolated superior cervical ganglia were treated with 0.3 mg /ml trypsin, 0.45 mg /ml collagenase D (Boehringer Mannheim, Indianapolis, I N), and 0.1 mg /ml DNase in Earle's balanced salt solution for 1 hr at 35°C in a shaking water bath. Then the flask was shaken vigorously by hand for 10 sec to dissociate the neurons. Dissociated neurons were plated onto poly-L-lysine-coated 35 mm culture dishes in M EM (Life Technologies, Gaithersburg, MD) with 10% fetal calf serum, 1% glutamine, and 1% penicillin -streptomycin. Neurons were incubated in a humidified incubator at 37°C in 5% CO 2 . After 4 -5 hr to allow neurons to attach to the culture dishes, CB1, CB1-417, or CB1-D164N plasmid cDNA was microinjected directly into the nucleus of single SCG neurons in concentrations of 50 or 100 ng /l in water. The pEGFP-N1 plasmid (10 ng /l) containing the coding sequence of the enhanced green fluorescent protein (C lontech, Palo Alto, CA) was used as a coinjection marker. The plasmid solution was centrif uged (16,000 ϫ g) in nonheparinized hematocrit tubes for 20 min to remove suspended debris. Injection pipettes were pulled from fiber-filled capillary glass (1B120F-4; World Precision Instruments, Sarasota, FL) on a P-97 Flaming-Brown micropipette puller (Sutter Instrument, Novato, CA). SCG neurons were microinjected with an Eppendorf 5246 transjector and 5171 micromanipulator (Madison, W I), using an injection pressure of 75-100 hPa and an injection time of 0.3-0.4 sec.
Electrophysiolog ical recording of Ca 2ϩ currents. Ca 2ϩ currents from rat SCG neurons were recorded at room temperature (22-26°C) 16 -20 hr after injection by the whole-cell variant of the patch-clamp technique (Hamill et al., 1981) with an Axopatch 200A patch-clamp amplifier (Axon Instruments, Foster C ity, CA). The pipettes for patch recording were pulled from borosilicate glass capillaries (Corning 7052; Garner Glass, C laremont, CA). Patch electrodes were coated with Sylgard 184 (Dow Corning, Midland, M I) and fire-polished on a microforge (Narishige, Tokyo, Japan). Pipette resistances ranged from 2.8 to 3.5 M⍀ when filled with the internal solution described below. The cell membrane capacitance and series resistance were compensated electronically to Ͼ80%. Whole-cell currents were low-pass filtered at 5 kHz, using the Bessel filter of the clamp amplifier.
Voltage-clamp protocols were generated with a Power Macintosh 8600/200 computer (Apple Computer, Cupertino, CA) equipped with a PCI-16 Host Interface card connected to an I TC -16 Data Acquisition Interface (Instrutech, Port Washington, N Y) using Pulse Control 5.0 extended operations (Richard J. Bookman, Jack D. Herrington, and Kenneth R. Newton, University of Miami, Miami, FL) with IGOR software (WaveMetrics, Lake Oswego, OR). C a 2ϩ currents were elicited by voltage steps from a holding potential of Ϫ80 mV and digitized at 180 sec per point. A double-pulse protocol consisting of two 25 msec steps to ϩ5 mV was used to elicit C a 2ϩ currents. The first step to ϩ5 mV elicited the control C a 2ϩ current. The second step to ϩ5 mV was preceded by a 50 msec step to ϩ80 mV. The current elicited by the second voltage step to ϩ5 mV was facilitated when compared with the control current elicited by the first voltage step. Current amplitudes were measured isochronally 10 msec after the first voltage step to ϩ5 mV.
Solutions. To isolate C a 2ϩ currents for whole-cell recording, we bathed the cells in an external solution that contained (in mM): 140 tetraethylammonium methanesulfonate, 10 H EPES, 15 glucose, 10 CaCl 2 , and 0.0001 tetrodotoxin, pH 7.4 (adjusted with methanesulfonic acid). The intracellular solution consisted of (in mM): 120 N-methyl-Dglucamine, 20 tetraethylammonium chloride, 10 H EPES, 11 EGTA, 1 CaCl 2 , 4 Mg-ATP, 0.1 Na 2 -GTP, and 14 phosphocreatine, pH 7.2 (adjusted with methanesulfonic acid).
The SF-77B Perf usion Fast-Step device (Warner Instrument, Hamden, C T) was used to apply the cannabinoid receptor agonist W I N 55, 212-2 mesylate (RBI /Sigma, St. L ouis, MO), the cannabinoid receptor inverse agonist SR 141716A (a gift from Sanofi-Synthélabo, Paris, France), and the ␣ 2 -adrenergic agonist UK 14304 (RBI /Sigma). Stock solutions of 10 mM W I N 55,212-2, SR 141716A, and UK 14304 were prepared in dimethylsulfoxide. On the day of the experiment the stock solution of W I N 55,212-2, SR 141716A, and UK 14304 was diluted to 1 M in external solution and briefly sonicated (20 sec) to facilitate dispersion. This concentration of DMSO in external solution had no effect on the C a 2ϩ current. Results are presented as means Ϯ SEM where appropriate. Statistical significance was determined by Student's t test. The differences were considered significant at p Ͻ 0.05.
RESULTS

Deletion of the distal C-terminal tail enhances the constitutive activity and the ability of the CB1 cannabinoid receptor to sequester G-proteins
The C-terminal-truncated CB1-417 receptor in which amino acids 418 -472 were deleted was tested for both constitutive activity and G-protein sequestration. Constitutive activity of the CB1 cannabinoid receptor resulted in a tonic inhibition of the voltage-dependent Ca 2ϩ current that was reversed by the CB1 inverse agonist SR 141716A. Both the wild-type CB1 and the truncated CB1-417 receptors were constitutively active. SR 141716A increased the Ca 2ϩ current in neurons expressing CB1 and CB1-417 cannabinoid receptors (Fig. 1) . To compare the constitutive activity between the wild-type CB1 and truncated CB1-417 cannabinoid receptors, we injected two different concentrations of receptor cDNA into the nuclei of SCG neurons. In SCG neurons that were injected with 100 ng/l wild-type CB1 receptor cDNA, SR 141716A increased the Ca 2ϩ current 60.2 Ϯ 13.7% (n ϭ 10). In neurons that were injected with 100 ng/l CB1-417 cDNA, SR 141716A increased Ca 2ϩ current 110.0 Ϯ 2.3% (n ϭ 10) (Fig. 1) . The difference between these groups was not significant ( p ϭ 0.08). However, in neurons that were injected with 50 ng/l CB1-417 cDNA, the increase in the Ca 2ϩ current by SR 141716A was significantly ( p Ͻ 0.05) greater compared with the wild-type CB1 receptor. SR 141716A increased the Ca 2ϩ current 101.1 Ϯ 18.9% (n ϭ 5) in neurons that were injected with 50 ng/l CB1-417 cDNA compared with 43.1 Ϯ 7.5% (n ϭ 4) in neurons that were injected with 50 ng/l CB1 cDNA. These results indicate that at a reduced receptor population the number of C-terminal-truncated CB1-417 receptors that are in a constitutively active state is greater than the number of constitutively active wild-type CB1 receptors. To confirm these results, we tested the effect of the cannabinoid agonist WIN 55,212-2. Previous work has shown that the C-terminal-truncated CB1 receptor has a similar affinity for WIN 55,212-2 (Jin et al., 1999) . If the truncated CB1-417 cannabinoid receptor has a greater constitutive activity, then a larger number of the cannabinoid receptor population should be in the active R*G GTP state and a cannabinoid agonist would be predicted to have little additional effect. Inhibition of the Ca 2ϩ current by WIN 55,212-2 was significantly ( p Ͻ 0.05) smaller in neurons expressing the truncated CB1-417 receptor (Fig. 1) . WIN 55,212-2 (1 M) inhibited the Ca 2ϩ current 43.7 Ϯ 6.5% (n ϭ 7) in neurons expressing wild-type CB1 receptors compared with 22.6 Ϯ 3.0 (n ϭ 5) in neurons expressing the truncated CB1-417 receptors (Nie and Lewis, 2001) .
As an additional test of the enhanced constitutive activity of the CB1-417 receptor, we tested whether its ability to sequester G-proteins would be enhanced. We have shown previously that the wild-type CB1 cannabinoid receptor can sequester G-proteins and prevent ␣ 2 -adrenergic and somatostatin receptors from signaling (Vasquez and Lewis, 1999) . G-protein sequestration occurs because the receptor resides in both an inactive G-proteinprecoupled RG GDP state and a constitutively active R*G GTP state. If the truncated CB1-417 receptors primarily populate the constitutively active R*G GTP state by depopulating the inactive R state that is uncoupled from G-proteins, then as a population they should be better able to sequester G-proteins and prevent other receptors from signaling. To test this hypothesis, we injected SCG neurons with either 100 or 50 ng/l CB1 receptor cDNA and tested for native ␣ 2 -adrenergic receptor signaling. In SCG neurons the ␣ 2 -adrenergic receptor agonist UK 14304 inhibited the Ca 2ϩ current 44.5 Ϯ 5.7% (n ϭ 12) (Fig. 2C) . In neurons that were injected with either wild-type CB1 or CB1-417 cDNA (100 ng/l), the effect of UK 14304 was abolished ( p Ͻ 0.01). UK 14304 inhibited the Ca 2ϩ current only 1.5 Ϯ 4.2% (n ϭ 4) in neurons expressing CB1 receptors and 0.2 Ϯ 2.0% (n ϭ 5) in neurons expressing CB1-417 receptors (Fig. 2C) . However, when the wild-type CB1 cDNA concentration was reduced to 50 ng/l, the effect of the ␣ 2 -adrenergic agonist UK 14304 was partially restored (Fig. 2 A,C) . UK 14304 inhibited the Ca 2ϩ current 20.0 Ϯ 3.6% (n ϭ 4) in neurons that were injected with 50 ng/l CB1 cDNA. In contrast, in SCG neurons that were injected with 50 ng/l CB1-417 cDNA the UK 14304 still had no effect (Fig.  2 B,C) . UK 14304 inhibited the Ca 2ϩ current 0.6 Ϯ 1.2% (n ϭ 5) in neurons that were injected with 50 ng/l CB1-417 cDNA. These results suggest that the truncated CB1-417 receptor has an enhanced ability to sequester G-proteins.
The partial restoration of ␣ 2 -adrenergic receptor signaling in neurons that were injected with 50 ng/l wild-type CB1 cDNA was abolished after the application of the inverse agonist SR 141716A (1 M) (Fig. 2 A) . SR 141716A traps the CB1 cannabinoid receptor in its inactive G-protein-precoupled RG GDP state and prevents the G-proteins from coupling to ␣ 2 -adrenergic receptors. In neurons that were injected with 50 ng/l CB1 cDNA, the first application of UK 14304 inhibited the Ca 2ϩ current 20.0 Ϯ 3.6% (n ϭ 4). After application of SR 141716A the UK 14304 inhibited the Ca 2ϩ current only 6.7 Ϯ 3.0% (n ϭ 4) ( Fig.  2C ) in agreement with our previous work (Vasquez and Lewis, 1999) . In contrast, in neurons that were injected with 50 ng/l CB1-417 cDNA, the effect of UK 14304 was no different either before or after SR 141716A. In neurons that were injected with 50 ng/l CB1-417 cDNA, UK 14304 inhibited the Ca 2ϩ current 0.6 Ϯ 1.2% (n ϭ 5) before the application of SR 141716A and 0.6 Ϯ 1.0% (n ϭ 5) after SR 141716A (Fig. 2C) .
Mutation of aspartate in the second transmembrane domain of the CB1 receptor abolishes constitutive activity and G-protein sequestration
Mutation of aspartate in the second transmembrane domain of the rat CB1 cannabinoid receptor, CB1-D164N, disrupts activation of inwardly rectifying K ϩ channels while leaving Ca 2ϩ channel modulation intact . Because modulation of both ion channels is mediated by receptor activation of G-proteins, we hypothesized that the D164N mutation impairs G-protein coupling. Wild-type CB1 cannabinoid receptors exist in an inactive G-protein-precoupled RG GDP state and a constitutively active R*G GTP state. The wild-type CB1 receptor also is predicted to populate an inactive G-protein-uncoupled R state. We hypothesized that the D164N mutation destabilizes the receptor such that more of the receptors are in the inactive R state uncoupled from G i /o -proteins. Thus we predicted that the mutant CB1-D164N receptor would not be constitutively active and would not sequester G-proteins. If the CB1-D164N receptor is not constitutively active, then the CB1 inverse agonist SR 141716A should have little effect. If the CB1-D164N receptor does not sequester G-proteins, then signaling by the ␣ 2 -adrenergic receptor should not be affected. In SCG neurons that were injected with CB1-D164N cDNA (100 ng/l), the cannabinoid agonist WIN 55,212-2 (1 M) inhibited the Ca 2ϩ current (Fig. 3A) in agreement with the results of others . Ca 2ϩ current inhibition was similar for both CB1-D164N
and wild-type CB1 receptors. WIN 55,212-2 inhibited the Ca 2ϩ current 34.2 Ϯ 4.8% (n ϭ 6) in neurons expressing CB1-D164N receptors compared with 43.7 Ϯ 6.5% (n ϭ 7) in neurons expressing CB1 receptors (Fig. 4 A) . However, unlike for the wild-type CB1 receptors the effect of SR 141716A was abolished ( p Ͻ 0.05) in neurons expressing CB1-D164N receptors. In an SCG neuron expressing CB1-D164N receptors, SR 141716A (1 M) produced a very small increase in the Ca 2ϩ current (Fig. 3B) . SR 141716A increased the Ca 2ϩ current 60.2 Ϯ 13.7% (n ϭ 10) in neurons expressing wild-type CB1 receptors but only by 11.6 Ϯ 6.9% (n ϭ 5) in neurons expressing CB1-D164N receptors (Fig. 4 B) . Thus the CB1-D164N receptor does not appear to be constitutively active. Figure 2 . G-protein sequestration is enhanced by truncation of the distal C-terminal tail of the CB1 cannabinoid receptor. A, Left, In an SCG neuron that was injected with 50 ng/l CB1, the cDNA application of the ␣ 2 -adrenergic agonist UK 14304 (UK ) produced a small inhibition of the Ca 2ϩ current. Application of the CB1 cannabinoid receptor inverse agonist SR 141716A (SR) increased the Ca 2ϩ current and blocked the effect of a subsequent application of UK 14304. A, Right, Superimposed current traces in the absence (Control ) and presence of the first and second application of UK 14304 (UK ) and SR 141716A (SR). B, Left, In an SCG neuron that was injected with 50 ng/l CB1-417, cDNA application of UK 14304 had no effect on the Ca 2ϩ current. Application of SR 141716A produced a large increase in the Ca 2ϩ current, and a subsequent application of UK 14304 also had no effect. B, Right, Superimposed current traces in the absence (Control ) and presence of the first and second application of UK 14304 (UK ) and SR 141716A (SR). C, Bar graph of Ca 2ϩ current inhibition by UK 14304 in neurons expressing wild-type CB1 or truncated CB1-417 receptors from cDNA injections at the concentrations indicated in the table. The effect of UK 14304 in control neurons was abolished in neurons that were injected with 100 ng/l CB1 or CB1-417 cDNA. The effect of UK 14304 was partially restored in neurons that were injected with 50 ng/l CB1, but not with CB1-417 cDNA. The effect of UK 14304 was abolished after the application of SR 141716A for CB1-injected neurons (50 ng/l). **p Ͻ 0.01 relative to wild-type CB1. To test whether CB1-D164N receptors can sequester G-proteins, we tested the ␣ 2 -adrenergic agonist UK 14304 in neurons that were injected with 100 ng/l CB1-D164N cDNA. In SCG neurons expressing CB1-D164N receptors, UK 14304 (1 M) produced a robust inhibition of the Ca 2ϩ current (Fig. 3) . The effect of UK 14304 was no different between uninjected control neurons and neurons that were injected with CB1-D164N cDNA. UK 14304 inhibited the Ca 2ϩ current 44.5 Ϯ 5.7% (n ϭ 12) in control neurons and 35.8 Ϯ 6.8% (n ϭ 5) in neurons expressing CB1-D164N receptors (100 ng/l cDNA-injected) (Fig. 5) . In contrast, UK 14304 had no effect (1.5 Ϯ 4.2%; n ϭ 4) in neurons expressing wild-type CB1 receptors (100 ng/l cDNA-injected) (Fig. 5) . Thus mutation of aspartate in the second transmembrane domain of the CB1 receptor abolished the ability of the CB1 receptor to sequester G-proteins and interfere with signaling by the G-protein-coupled ␣ 2 -adrenergic receptor.
G-protein sequestration by the wild-type CB1 receptor can occur in both inactive RG GDP and active R*G GTP receptor conformations (Vasquez and Lewis, 1999) . Because the mutant CB1-D164N receptor failed to sequester G-proteins, we predicted that this receptor fails to adopt the inactive G-protein-precoupled RG GDP conformation. To determine whether the mutant CB1-D164N receptor can adopt the inactive G-protein-precoupled RG GDP state, we tested the ability of SR 141716A to stabilize the RG GDP state. We have shown previously that SR 141716A acting on the wild-type CB1 receptor can sequester G-proteins by trapping the CB1 receptor in the RG GDP conformation and preventing signaling by the ␣ 2 -adrenergic receptor (Vasquez and Lewis, 1999) . SR 141716A failed to abolish the inhibition of the Ca 2ϩ current by the ␣ 2 -adrenergic agonist UK 14304 in neurons expressing CB1-D164N receptors (100 ng/l). Ca 2ϩ current inhibition by UK 14304 (1 M) was 35.8 Ϯ 6.8% (n ϭ 5) before and 44.7 Ϯ 5.0% (n ϭ 4) after the application of SR 141716A (Fig. 5) .
Thus the CB1-D164N receptor, unlike the wild-type CB1 receptor, does not precouple to G-proteins in their inactive RG GDP state. These results suggest that the CB1-D164N receptor occupies an inactive state uncoupled from G-proteins but can couple to G-proteins in the presence of the cannabinoid agonist WIN 55,212-2 (Figs. 3A, 4A ).
DISCUSSION
CB1 cannabinoid receptors are constitutively active, which results in a tonic inhibition of Ca 2ϩ channels when expressed in SCG neurons. The CB1 cannabinoid receptors reside in two G-proteincoupled states, a constitutively active R*G GTP and an inactive RG GDP state (Bouaboula et al., 1997; Vasquez and Lewis, 1999) . By stabilizing the inactive RG GDP state, the CB1 inverse agonist SR 141716A reverses the constitutive activity by depopulating the active R*G GTP state. SR 141716A thus enhances the Ca 2ϩ current in neurons expressing the CB1 receptors. By stabilizing the inactive RG GDP state, SR 141716A also prevents these G-proteins from interacting with other G-protein-coupled receptors.
In the present study SR 141716A produced a greater enhancement of the Ca 2ϩ current when the distal C-terminal tail of the CB1 receptor was truncated. When 50 ng/l cDNA was injected into SCG neurons, the enhancement of the Ca 2ϩ current in the presence of SR 141716A was significantly ( p Ͻ 0.05) greater for the C-terminal-truncated CB1-417 cannabinoid receptor compared with the wild-type CB1 receptor. However, when the cDNA injection concentration was 100 ng/l, the enhancement of the Ca 2ϩ current in the presence of SR 141716A approached but was not significantly ( p ϭ 0.08) greater for the CB1-417 cannabinoid receptor compared with the wild-type CB1 receptor. At the 100 ng/l injection concentration both the wild-type CB1 and the C-terminal-truncated CB1-417 receptor populations are greater; therefore, the number of receptors that are constitutively active is greater. When the receptor density was reduced by injecting 50 ng/l receptor cDNA, SR 141716A produced a larger increase in the Ca 2ϩ current in neurons expressing CB1-417 receptors compared with wild-type CB1 receptors. Thus truncation of the distal C-terminal tail of the cannabinoid receptor promotes the constitutively active R*G GTP conformational state of the receptor. If a receptor is already in the active R*G GTP conformation, then the effect of the cannabinoid agonist WIN 55,212-2, which stabilizes the active R*G GTP state, would be predicted to have little additional effect. Consistent with this prediction, the effect of WIN 55,212-2 on both the Ca 2ϩ channels and the inwardly rectifying K ϩ channels was reduced by truncation of the distal C terminal (Jin et al., 1999; Nie and Lewis, 2001) . The distal C-terminal tail of the cannabinoid receptor thus acts to constrain the receptor to its inactive RG GDP conformation and slows its transition to the active R*G GTP conformation.
Several other studies on G-protein-coupled receptors also have shown a role for the C terminal in constitutive activity. Deletion of the C terminal of the ␤-adrenergic receptor enhances its constitutive activity (Parker and Ross, 1991) , and the constitutive activity of the D5 dopamine receptor is critically dependent on the C terminal (Demchyshyn et al., 2000) . Additionally, shorter C-terminal variants of 5-HT4 receptors have been shown to have greater constitutive activity (Claeysen et al., 1999) . Thus, for a subset of G-protein-coupled receptors that show constitutive activity, the C-terminal tail appears to play a critical role in limiting G-protein activation. Figure 5 . The CB1-D164N cannabinoid receptor does not sequester G-proteins. Bar graph of Ca 2ϩ current inhibition by the ␣ 2 -adrenergic agonist UK 14304 in uninjected control SCG neurons and in neurons expressing wild-type CB1 or CB1-D164N receptors. The effect of UK 14304 was abolished in neurons that were injected with wild-type CB1 receptor cDNA, but not in neurons that were injected with CB1-D164N cDNA. The effect of UK 14304 was no different in neurons expressing CB1-D164N receptors after the application of SR 141716A (1 M). The concentration of receptor cDNA that was injected and the application of SR 141716A are indicated in the table. **p Ͻ 0.01 relative to control neurons or CB1-D164N-injected neurons.
